FDA Downgrades Ketamine ANDA Amendment to Minor, Sets November 10 Goal Date

summarizeSummary

FDA reclassified NRx's ketamine ANDA amendment from Major to Minor and set a November 10, 2026 GDUFA goal date, de-risking the approval path for NRX-100.

check_boxKey Events · Product Development and Regulatory · NRXP

• FDA Downgrades ANDA Amendment

  The FDA Office of Generic Drugs reclassified NRx's ketamine ANDA amendment from Major to Minor, indicating the submission will not require substantial FDA resources.

• New GDUFA Goal Date Set

  The acknowledgement letter revised the GDUFA goal date to November 10, 2026, providing a concrete near-term approval timeline for NRX-100.

• Regulatory De-risking

  A Major amendment would have reset the review clock; the Minor classification signals the FDA views the application as straightforward, reducing approval uncertainty.

• Going-Concern Backdrop

  The regulatory progress comes amid a going-concern warning and $16.5M Q2 net loss, making the ketamine ANDA approval critical to the company's cash runway and survival.

auto_awesomeAnalysis · NRXP · Life Sciences

The FDA reclassified NRx's ketamine ANDA amendment from Major to Minor, a meaningful regulatory de-risking event. A Major amendment would have reset the review clock and required substantial FDA resources; a Minor amendment signals the agency sees the submission as straightforward. The revised GDUFA goal date of November 10, 2026 gives investors a concrete near-term approval catalyst for NRX-100, the company's preservative-free ketamine product targeting suicidal depression. This comes amid a going-concern warning and a $16.5M Q2 loss, so regulatory progress is critical to the company's survival narrative.